All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-09-05T09:10:16.000Z

Ibrutinib did not meet the primary efficacy endpoint in patients with R/R FL in the phase II DAWN study

Sep 5, 2018
Share:

Bookmark this article

On 31st May 2018, results from the phase II DAWN study were published in the Journal of Clinical Oncology by Ajay K. Gopal, Fred Hutchinson Cancer Research Center, Seattle, Washington, and colleagues. The study evaluated the efficacy and safety of ibrutinib in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

Study Overview

  • N = 110 patients with R/R FL were included in the study. 67% of patients were male and the median age was 61.5 years (range, 28–87). Patients had a median of 3 prior lines of therapy
  • Patients were treated with ibrutinib 560 mg daily until disease progression or unacceptable toxicity
  • The primary endpoint was overall response rate (ORR) assessed by an independent review committee (IRC)
  • Secondary endpoints included; duration of response (DOR), progression-free survival (PFS), time-to-next-treatment (TTNT) and overall survival (OS)

Key Findings

  • Median follow-up was 27.7 months
  • ORR = 20.9% (95% CI, 13.7–29.7%)
    • N = 12 patients had a complete response (CR) 11% (95% CI, 5.8–18.3%)
    • The study, therefore, did not meet its primary objective, defined as an ORR with the lower bound threshold of >18%
  • Median DOR = 19.4 months
  • Median PFS = 4.6 months (95% CI, 2.8–5.5)
  • Median TTNT = 16 months (95% CI, 10.7–19.1)
  • 30-month OS = 61% (95% CI, 0.51–0.70%)
  • Most frequent adverse events (AEs) grade ≥3 included; neutropenia (n = 15), anemia (n = 10) and fatigue (n = 6)
    • N = 8 deaths were reported during the study. 2 fatal AE cases were considered possibly related to ibrutinib (neutropenic sepsis and pneumonia)

The authors concluded that since the study did not meet its primary endpoint, ibrutinib monotherapy cannot be supported in patients with R/R FL.

  1. Gopal AK. Et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study. Journal of Clinical Oncology. 2018 May 31: JCO2017768853. doi: 10.1200/JCO.2017.76.8853. [Epub ahead of print]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox